OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free TRLPF Stock Alerts $0.12 0.00 (-3.75%) (As of 04/30/2019) Add Compare Share Share Today's Range$0.12▼$0.1250-Day Range$0.22▼$0.2252-Week Range$0.08▼$0.34Volume25,000 shsAverage Volume5,474 shsMarket Capitalization$29.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Acerus Pharmaceuticals Stock (OTCMKTS:TRLPF)Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More TRLPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRLPF Stock News HeadlinesFebruary 8, 2024 | wsj.comTakeda Pharmaceutical Co. Ltd. ADRJanuary 1, 2023 | seekingalpha.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitAugust 9, 2022 | financialpost.comAcerus Reports Second Quarter 2022 Financial ResultsMarch 15, 2022 | financialpost.comAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsSee More Headlines Company Calendar Last Earnings11/05/2018Today5/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:TRLPF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,790,000.00 Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales4.05 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$29.87 million OptionableNot Optionable Beta2.60 Key ExecutivesMs. Patricia SymmesChief Operating OfficerDr. Nathan BrysonChief Scientific OfficerMr. Philippe SavardVP, Gen. Counsel & Corp. Sec.Mr. Edward GudaitisPres , CEO & DirectorMr. Robert M. MotzChief Financial OfficerKey CompetitorsKezar Life SciencesNASDAQ:KZRCarisma TherapeuticsNASDAQ:CARMCheckpoint TherapeuticsNASDAQ:CKPTCalciMedicaNASDAQ:CALCKronos BioNASDAQ:KRONView All Competitors TRLPF Stock Analysis - Frequently Asked Questions How have TRLPF shares performed in 2024? Acerus Pharmaceuticals' stock was trading at $0.22 at the start of the year. Since then, TRLPF shares have decreased by 47.5% and is now trading at $0.1155. View the best growth stocks for 2024 here. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative trailing twelve-month return on equity of 346.72% and a negative net margin of 254.66%. How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TRLPF) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist My Default Watchlist Adding Acerus Pharmaceuticals Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.